MX2022007203A - Construcciones quimericas de interleucina 2. - Google Patents

Construcciones quimericas de interleucina 2.

Info

Publication number
MX2022007203A
MX2022007203A MX2022007203A MX2022007203A MX2022007203A MX 2022007203 A MX2022007203 A MX 2022007203A MX 2022007203 A MX2022007203 A MX 2022007203A MX 2022007203 A MX2022007203 A MX 2022007203A MX 2022007203 A MX2022007203 A MX 2022007203A
Authority
MX
Mexico
Prior art keywords
interleukin
chimeric constructs
c4bpî2
moiety
fragment
Prior art date
Application number
MX2022007203A
Other languages
English (en)
Inventor
Jérémie Mariau
David Klatzmann
Nicolas Billiald
Thomas Vazquez
Original Assignee
Iltoo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iltoo Pharma filed Critical Iltoo Pharma
Publication of MX2022007203A publication Critical patent/MX2022007203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención se refiere a una construcción quimérica, que comprende i) una porción de interleucina 2 (IL2) y ii) una cadena beta de la proteína de unión a C4b (C4BPß) o por lo menos un fragmento o variante funcional del mismo que es capaz de formar una proteína dimérica.
MX2022007203A 2019-12-12 2020-12-11 Construcciones quimericas de interleucina 2. MX2022007203A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306637 2019-12-12
PCT/EP2020/085830 WO2021116444A1 (en) 2019-12-12 2020-12-11 Interleukin 2 chimeric constructs

Publications (1)

Publication Number Publication Date
MX2022007203A true MX2022007203A (es) 2022-10-18

Family

ID=69232735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007203A MX2022007203A (es) 2019-12-12 2020-12-11 Construcciones quimericas de interleucina 2.

Country Status (12)

Country Link
US (1) US20230036793A1 (es)
EP (1) EP4073094A1 (es)
JP (1) JP2023505590A (es)
KR (1) KR20220139293A (es)
CN (1) CN115190885A (es)
AU (1) AU2020401357A1 (es)
BR (1) BR112022011414A2 (es)
CA (1) CA3159468A1 (es)
IL (1) IL293628A (es)
MX (1) MX2022007203A (es)
WO (1) WO2021116444A1 (es)
ZA (1) ZA202206740B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3233644A1 (en) * 2021-10-06 2023-04-13 David Klatzmann Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
CA1340265C (en) 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
FR2869323B1 (fr) * 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
EP2382228B1 (en) 2009-01-21 2020-08-26 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
US8437577B2 (en) 2009-03-05 2013-05-07 Tektronix, Inc. Methods and systems for image registration
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
SI3172227T1 (sl) 2014-07-21 2020-02-28 Delinia, Inc. Molekule, ki selektivno aktivirajo regulatorne T celice, za zdravljenje avtoimunskih bolezni
AU2016341241B9 (en) 2015-10-22 2021-11-18 Iltoo Pharma Pharmaceutical compositions of IL-2
EP3280725B1 (en) 2016-05-04 2020-08-26 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Also Published As

Publication number Publication date
IL293628A (en) 2022-08-01
EP4073094A1 (en) 2022-10-19
KR20220139293A (ko) 2022-10-14
JP2023505590A (ja) 2023-02-09
CN115190885A (zh) 2022-10-14
BR112022011414A2 (pt) 2022-08-30
WO2021116444A1 (en) 2021-06-17
AU2020401357A1 (en) 2022-07-21
US20230036793A1 (en) 2023-02-02
ZA202206740B (en) 2023-06-28
CA3159468A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
MX2022007203A (es) Construcciones quimericas de interleucina 2.
EA202190983A1 (ru) Новое антитело к с-kit
MX2020011133A (es) Composiciones de pienso para animales y usos de las mismas.
MX354923B (es) Inmunocitosinas basadas en un dominio sushi de il-15 y de il-15ra.
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
PH12020551716A1 (en) Anti-ror antibody constructs
DE60335640D1 (de) Polypeptide der gh-61-familie
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MY194084A (en) Interferon beta antibodies and uses thereof
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CO2022007920A2 (es) Conjugados de anticuerpo-fármaco dirigido a la claudina 18.2
MX2021015761A (es) Polipeptidos.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
PE20210419A1 (es) Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
MX2021014149A (es) Producto de confiteria.
MX2020010092A (es) Variantes de anticuerpo c-terminales.
JOP20210339A1 (ar) أجسام مضادة لـ angpt2
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами
MX2020008295A (es) Polipeptidos, composiciones y sus usos.
MX2022004545A (es) Composiciones de pienso animal y usos de las mismas.
MX2022013209A (es) Metodos de escision de polipeptidos.
EA202092204A1 (ru) Композиции
MX2021015922A (es) Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
MX2022009661A (es) Tratamiento de enfermedades asociadas a panx1.
IT201900022575A1 (it) Linea di convogliamento e selezione di prodotti ortofrutticoli oblunghi.